Patents by Inventor Andrew Sharpe

Andrew Sharpe has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130018057
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by a fused bicyclic pyridine or pyrimidine moiety attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of P13 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 17, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Roland Bürli, Alan Findlay Haughan, Mîzio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Publication number: 20130012517
    Abstract: A series of quinoline and quinoxaline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: November 11, 2010
    Publication date: January 10, 2013
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Patent number: 8324204
    Abstract: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Grant
    Filed: June 4, 2007
    Date of Patent: December 4, 2012
    Assignee: UCB Pharma SA
    Inventors: Rikki Peter Alexander, Stuart Bailey, Stephen Brand, Daniel Christopher Brookings, Julien Alistair Brown, Alan Findlay Haughan, Natasha Kinsella, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Marianna Dilani Richard, Andrew Sharpe, Laura Jane Tait
  • Publication number: 20120277166
    Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
    Type: Application
    Filed: May 25, 2011
    Publication date: November 1, 2012
    Applicant: XENOME LIMITED
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
  • Publication number: 20120095005
    Abstract: A series of substituted pyrazolo[1,5-?][1,3,5]triazine and pyrazolo[1,5-?j-pyrimidine derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions. Formula (I).
    Type: Application
    Filed: May 19, 2010
    Publication date: April 19, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Barry John Langham, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Andrew Sharpe
  • Publication number: 20120077815
    Abstract: A series of amino-substituted fused pyridine and pyrazine derivatives, in particular amino-substituted quinoline and quinoxaline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: February 11, 2010
    Publication date: March 29, 2012
    Applicant: UCB PHARMA S.A.
    Inventors: Daniel Rees Allen, Julien Alistair Brown, Roland Burli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20120053167
    Abstract: A series of substituted [1,3,5]triazin-2-yl derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: March 2, 2010
    Publication date: March 1, 2012
    Applicant: UCB PHARMA, S.A.
    Inventors: Daniel Rees Allen, Roland Bürli, Alan Findlay Haughan, Jonathan David MacDonald, Mizio Matteucci, David John Nash, Andrew Pate Owens, Gilles Raphy, Elizabeth Anne Saville-Stones, Andrew Sharpe
  • Publication number: 20120028503
    Abstract: An adaptor is shaped for allowing use of a micro SIM card in a mini SIM card implemented device. An adaptor body is shaped like a micro SIM card and may include a cutout region for receiving a micro SIM card therein.
    Type: Application
    Filed: December 9, 2010
    Publication date: February 2, 2012
    Inventors: Cameron Alan Holmes, William Andrew Sharpe, Odette Kim Holmes
  • Publication number: 20110105508
    Abstract: A series of heteroaryl-substituted quinoxaline and quinoline derivatives, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: December 17, 2008
    Publication date: May 5, 2011
    Applicant: UCB PHARMA, S.A.
    Inventors: Daniel Rees Allen, George Martin Buckley, Roland Bürli, John Richard Davenport, Natasha Kinsella, Christopher James Lock, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Andrew James Ratcliffe, Marianna Dilani Richard, Verity Margaret Sabin, Andrew Sharpe, Laura Jane Tait, Graham John Warrelow, Sophie Caroline Williams
  • Publication number: 20100305066
    Abstract: A series of 5,6-dihydro-1-benzothiophen-7(4H)-one derivatives, and analogues thereof, which are substituted in the 2-position by an optionally substituted morpholin-4-yl moiety, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
    Type: Application
    Filed: June 4, 2007
    Publication date: December 2, 2010
    Applicant: UCB PHARMA S.A.
    Inventors: Rikki Peter Alexander, Stuart Bailey, Stephen Brand, Daniel Christopher Brookings, Julien Alistair Brown, Alan Findlay Haughan, Natasha Kinsella, Christopher Lowe, Stephen Robert Mack, William Ross Pitt, Marianna Dilani Richard, Andrew Sharpe, Laura Jane Tait
  • Patent number: 7752742
    Abstract: Systems and methods for providing a sealed container having a reduced pressure atmosphere are disclosed. The container is suitable for housing an infrared detector array. Outgassing can be enhanced by adding features to solder preforms that maintain pathways for gasses to more readily exit the container prior to sealing thereof. Getters can be used to mitigate undesirable gases within the sealed container. One or more bolometers can be used to determine if the sealed container is leaking. A vacuum positioning fixture can be used to assemble the components of the infrared detector assembly and to place the infrared detector assemblies into a vacuum chamber. The cost of manufacturing such infrared detector assemblies may be reduced and the reliability thereof enhanced.
    Type: Grant
    Filed: August 19, 2008
    Date of Patent: July 13, 2010
    Assignee: Flir Systems, Inc.
    Inventors: Paul Schweikert, William J. Parrish, Andrew Sharpe, Vu L. Nguyen, Marco Scussat
  • Publication number: 20090275498
    Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
    Type: Application
    Filed: November 2, 2007
    Publication date: November 5, 2009
    Applicant: The University of Queensland
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
  • Patent number: 7470904
    Abstract: Systems and methods for providing a sealed container having a reduced pressure atmosphere are disclosed. The container is suitable for housing an infrared detector array. Outgassing can be enhanced by adding features to solder preforms that maintain pathways for gasses to more readily exit the container prior to sealing thereof. Getters can be used to mitigate undesirable gases within the sealed container. One or more bolometers can be used to determine if the sealed container is leaking. A vacuum positioning fixture can be used to assemble the components of the infrared detector assembly and to place the infrared detector assemblies into a vacuum chamber. The cost of manufacturing such infrared detector assemblies may be reduced and the reliability thereof enhanced.
    Type: Grant
    Filed: March 20, 2006
    Date of Patent: December 30, 2008
    Assignee: Flir Systems, Inc.
    Inventors: Paul Schweikert, William J. Parrish, Andrew Sharpe, Vu L. Nguyen, Marco Scussat
  • Patent number: 7326682
    Abstract: The invention relates to an isolated, synthetic or recombinant ?-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
    Type: Grant
    Filed: August 13, 2004
    Date of Patent: February 5, 2008
    Assignee: Xenome Limited
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
  • Publication number: 20060276507
    Abstract: A class of piperidine and related heterocyclic derivatives, C-substituted by a substituted aryl or heteroaryl moiety, and N-substituted by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.
    Type: Application
    Filed: June 18, 2004
    Publication date: December 7, 2006
    Applicant: Celltech R&D Limited
    Inventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
  • Publication number: 20060241118
    Abstract: A class of piperazine and related heterocyclic derivatives, substituted at the 4-position by a substituted aryl or heteroaryl moiety, and at the 1-position by an ethylsulfonyl group which in turn is substituted at the 2-position by a hydroxamic acid moiety and also by a range of alternative substituents, being potent inhibitors of CD23 shedding, are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases.
    Type: Application
    Filed: June 18, 2004
    Publication date: October 26, 2006
    Applicant: Celltech R&D Limited
    Inventors: David Owen, Robert Watson, Daniel Allen, Andrew Sharpe, Hazel Dyke
  • Patent number: 6849601
    Abstract: The present invention relates to novel peptides and derivatives thereof useful as selective ?1-adrenoceptor antagonists which ability of inhibiting the agonist action of agonist noradrenaline on the ?1-adrenoceptor is greater than their ability of inhibiting the action of agonist noradrenaline on the other ?-adrenoceptors. The invention also relates to pharmaceutical compositions comprising these peptides.
    Type: Grant
    Filed: October 1, 1999
    Date of Patent: February 1, 2005
    Assignee: The University of Queensland
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe
  • Publication number: 20040266764
    Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.
    Type: Application
    Filed: July 29, 2004
    Publication date: December 30, 2004
    Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Andrew Sharpe, Andrew Douglas Baxter
  • Patent number: 6809100
    Abstract: The invention encompasses novel compounds which are inhibitors of matrix metalloproteinase, ADAM or ADAM-TS enzymes, and which are useful for the treatment of diseases mediated by those enzymes, including degenerative diseases and certain cancers.
    Type: Grant
    Filed: May 15, 2001
    Date of Patent: October 26, 2004
    Assignee: Darwin Discovery Ltd.
    Inventors: Duncan Robert Hannah, Hazel Joan Dyke, Andrew Sharpe, Andrew Douglas Baxter
  • Patent number: 6794361
    Abstract: The invention relates to an isolated, synthetic or recombinant &khgr;-conotoxin peptide having the ability to inhibit a neuronal amine transporter, nucleic acid molecules encoding all or part of such peptides, antibodies to such peptides and uses and methods of treatment involving them.
    Type: Grant
    Filed: June 27, 2001
    Date of Patent: September 21, 2004
    Assignee: The University of Queensland
    Inventors: Richard James Lewis, Paul Francis Alewood, Iain Andrew Sharpe